Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Zeshan Ahmad

Clinical Cardiac Electrophysiology Baltimore, MD Medical Doctor

NPI 1124439682 CMS profile 907627

600 N Wolfe St, Baltimore, MD 21287

Open in the dashboard

General payments

$37,041

287 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Zeshan Ahmad of Baltimore, MD is reported in the CMS Open Payments database as having received $37,041 across 287 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,809 37
2024 General $3,331 42
2023 General $7,095 73
2022 General $6,356 104
2021 General $147 7
2020 General $16,881 7
2019 General $422 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zeshan Ahmad
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Zeshan Ahmad were reported at $2,809. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Zeshan Ahmad Clinical Cardiac Electrophysiology median Middle half National median
2019 $422 $2,361 $585–$8,260 $163
2020 $16,881 $993 $247–$4,351 $114
2021 $147 $1,185 $326–$4,739 $132
2022 $6,356 $2,073 $554–$6,789 $149
2023 $7,095 $2,568 $759–$8,159 $160
2024 $3,331 $2,557 $703–$7,403 $164
2025 $2,809 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $16,928 14 payments
  2. Abbott Laboratories $11,386 155 payments
  3. Medtronic, Inc. $5,190 58 payments
  4. Biosense Webster, Inc. $3,031 43 payments
  5. Medtronic Vascular, Inc. $329 11 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $125 3 payments
  7. Janssen Pharmaceuticals, Inc $29 2 payments
  8. Pfizer Inc. $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $16,688 2 payments
  2. Food and Beverage $13,017 241 payments
  3. Travel and Lodging $7,266 43 payments
  4. Education $70 1 payment
Products named General payments · program years 2019–2025
  1. GENERAL - BRADY $15,000 1 payment
  2. Carto 3 $2,640 36 payments
  3. AVEIR Cardiac Rhythm Management $2,303 12 payments
  4. Micra $1,923 20 payments
  5. TactiCath SE $1,688 1 payment
  6. AMPLATZER AMULET $1,063 9 payments
  7. ENSITE $939 17 payments
  8. EVERA MRI XT DR SURESCAN $914 9 payments
  9. ADVISOR $764 7 payments
  10. AVEIR Structural Heart $529 3 payments
  11. Other $6,759 151 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

605

Median for Cardiology: 2,533

Drug cost

$201,694

Median for Cardiology: $485,213

Branded share of claims

25.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 114 $163,536
Xarelto Rivaroxaban Brand 18 $23,535
Dofetilide Generic 13 $6,591
Amiodarone Hcl Generic 84 $2,164
Metoprolol Succinate Generic 88 $1,416
Diltiazem 24hr Er (La) Diltiazem Hcl Brand 13 $824
Amlodipine Besylate Generic 55 $615
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 11 $577
Rosuvastatin Calcium Generic 17 $438
Atorvastatin Calcium Generic 31 $437

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$244,256

Medicare's payments for the services billed

Medicare patients

753

Average age 78

Services billed

2,162

416 women, 337 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 58%
Arthritis 53%
Ischemic heart disease 41%
Chronic kidney disease 34%
Heart failure 32%
Diabetes 30%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

287 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record